Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms

References

• Genazzani AA, Pattarino F. Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint. Drugs R D 2008;9:65-72
   PubMed Web of Science ®Google Scholar
• World Health Organization. Available at: http://www.who.int/trade/glossary/story034/en/index.html
   Google Scholar
• U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Orange Book – Approved drug products with therapeutic equivalence evaluations, 28th edn, 2008. Available at: http://www.fda.gov/cder/orange/obannual.pdf
   Google Scholar
• European Medicines Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP), Note for guidance on the investigation of bioavailability and bioequivalence, CPMP/EWP/QWP/1401/98, July 2001
   Google Scholar
• U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products – general considerations, March 2003
   Google Scholar
• Meredith PA, The Unique Adalat Story – Nifedipine Gastrointestinal Therapeutic System. European Cardiovascular Disease 2007; Issue 1, July 2007. Available at: http://www.touchbriefings.com/cdps/cditem.cfm?nid=2744&cid=5#Hypertension
   Google Scholar
• Verbeeck RK, Kanfer I, Walker RB. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. Eur J Pharm Sci 2006;28:1-6
   PubMed Web of Science ®Google Scholar
• Basak AK, Raw AS, Al Hakim AH, et al. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications. Adv Drug Deliv Rev 2007;59:64-72
   PubMed Web of Science ®Google Scholar
• Chen ML, Shah V, Patnaik R, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 2001;18:1645-50
   PubMed Web of Science ®Google Scholar
• Nakai K, Fujita M, Ogata H. International harmonization of bioequivalence studies and issues shared in common. Yakugaku Zasshi 2000;120:1193-200
   PubMed Web of Science ®Google Scholar
• Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003;25:2875-90
   PubMed Web of Science ®Google Scholar
• Birkett DJ. Generics – equal or not?. Austr Prescr 2003;26:85-7
   Google Scholar
• Besag FM. Is generic prescribing acceptable in epilepsy?. Drug Saf 2000;23:173-82
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA), CPMP Efficacy Working Party Therapeutic Subgroup on Pharmacokinetics (EWP-PK), July 2006. Available at: http://www.emea.europa.eu/pdfs/human/ewp/4032606en.pdf
   Google Scholar
• Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther 2005;43:485-98
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA), Therapeutic equivalence of generic drugs: Letter to health practitioners, January 1998. Available at: http://www.fda.gov/cder/news/nightgenlett.htm
   Google Scholar
• Mignini F, Tomassoni D, Traini E, et al. Single-dose, randomized, crossover bioequivalence study of amlodipine maleate versus amlodipine besylate in healthy volunteers. Clin Exp Hypertens 2007;29:539-52
   PubMed Web of Science ®Google Scholar
• Donnelly R, Meredith PA, Miller SH, et al. Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther 1993;54:303-10
   PubMed Web of Science ®Google Scholar
• Meredith PA. Generic drugs. Therapeutic equivalence. Drug Saf 1996;15:233-42
   Google Scholar
• Carter BL, Noyes MA, Demmler RW. Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy 1993;13:359-68
   PubMed Web of Science ®Google Scholar
• Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578-92
   PubMed Web of Science ®Google Scholar
• Nakai K, Fujita M, Ogata H. New bioequivalence studies: individual bioequivalence and population bioequivalence. Yakugaku Zasshi 2000;120:1201-8
   PubMed Web of Science ®Google Scholar
• Chen ML, Lesko LJ. Individual bioequivalence revisited. Clin Pharmacokinet 2001;40:701-6
   PubMed Web of Science ®Google Scholar
• Laroche ML, Merle L. Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation? Acta Clin Belg Suppl 2006;(1):48-50
   PubMedGoogle Scholar
• Furberg BD, Furberg CD. Are all drugs of a class interchangeable? In: Evaluating Clinical Research: All that Glitters is not Gold. New York: Springer, 2007:115-19
   Google Scholar
• Wiecek A, Mikhail A. European regulatory guidelines for biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v17-20
   PubMed Web of Science ®Google Scholar
• Davies G. Changing the salt, changing the drug. Pharm J 2001;266:322-3
   Google Scholar
• Frank RG. The ongoing regulation of generic drugs. N Engl J Med 2007;357:1993-6
   PubMed Web of Science ®Google Scholar
• Snider DA, Addicks W, Owens W. Polymorphism in generic drug product development. Adv Drug Deliv Rev 2004;56:391-5
   PubMed Web of Science ®Google Scholar
• Everett RM, Descotes G, Rollin M, et al. Nephrotoxicity of pravadoline maleate (WIN 48098-6) in dogs: evidence of maleic acid-induced acute tubular necrosis. Fundam Appl Toxicol 1993;21:59-65
   PubMedGoogle Scholar
• Olovson SG, Havu N, Regårdh CG, et al. Oesophageal ulcerations and plasma levels of different alprenolol salts: potential implications for the clinic. Acta Pharmacol Toxicol (Copenh) 1986;58:55-60
   PubMedGoogle Scholar
• U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for industry: Q3A impurities in new drug substances, June 2008
   Google Scholar
• U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for industry: Q3B(R2) impurities in new drug products, July 2006
   Google Scholar
• Amlodipine Citizen Petition by Pfizer Inc. Available at: http://www.fda.gov/ohrms/dockets/dailys/03/Sept03/090303/03p-0408-cp00001-08-Tab-G-vol3.pdf
   Google Scholar
• Sudhakar P, Nirmala M, Moses Babu J, et al. Identification and characterization of potential impurities of amlodipine maleate. J Pharm Biomed Anal 2006;40:605-13
   PubMed Web of Science ®Google Scholar
• Murakami T, Fukutsu N, Kondo J, et al. Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial amlodipine maleate tablets. J Chromatogr A 2008;1181:67-76
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP), Guideline on the limits of genotoxic impurities, EMEA/CHMP/QWP/251344/2006, London 2006
   Google Scholar
• Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991;41:478-505
   PubMed Web of Science ®Google Scholar
• Norvasc®. Pfizer Inc. Available at: http://www.fda.gov/cder/foi/label/2007/019787s042lbl.pdf
   Google Scholar
• Clavijo GA, de Clavijo IV, Weart CW. Amlodipine: a new calcium antagonist. Am J Hosp Pharm 1994;51:59-68
   PubMedGoogle Scholar
• Istin®. Pfizer Inc. Available at: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=1466
   Google Scholar
• Amlor®. Pfizer Inc. Available at: http://www.pfizer.fr/Portals/0/AMLOR%20Notice%20commune%205%20et%2010mg%20INT.pdf
   Google Scholar
• Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension 2007;50:181-8
   PubMed Web of Science ®Google Scholar
• Data on file. Pfizer Inc
   Google Scholar
• European Medicines Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP), Opinion following an article 29 referral: Amlovita. London 26 April 2004. EMEA/CPMP/539/04
   Google Scholar
• European Medicines Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP), Opinion following an article 29 referral: Talam. London 27 April 2004. EMEA/CPMP/540/04
   Google Scholar
• Park S, Chung N, Kwon J, et al. Results of a multicenter, 8-week, parallel-group, randomized, double-blind, double-dummy, phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension. Clin Ther 2005;27:441-50
   PubMed Web of Science ®Google Scholar
• New amlodipine (Amloc®) product available in South Africa. Cardiovasc J S Afr 2005;16:61
   Google Scholar
• Pragai G, Orosz E, Szilagyi J, et al. United States Patent Application Publication, US 2005/0019395 A1, January 27, 2005
   Google Scholar
• Harrison HE, Harrison HC. Experimental production of renal glycosuria, phosphaturia, and aminoaciduria by injection of maleic acid. Science 1954;120:606-8
   PubMed Web of Science ®Google Scholar
• Angielsky S, Rogulski J. Aminoaciduria caused by maleic acid. III. The effect of sulfhydryl compounds. Acta Biochim Pol 1959;6:411-15
   PubMed Web of Science ®Google Scholar
• Zager RA, Johnson AC, Naito M, et al. Maleate nephrotoxicity: mechanisms of injury and correlates with ischemic/hypoxic tubular cell death. Am J Physiol Renal Physiol 2008;294:F187-97
   PubMed Web of Science ®Google Scholar
• Makowiecka-Cieśla M, Januszewicz A, Prejbisz A, et al. Nine month follow-up of amlodipine maleate and amlodipine besylate treatment in patients with essential hypertension: does the salt form matter?. Arterial Hypertension 2005;9:364-73
   Google Scholar
• Elliott HL, Meredith PA, Reid JL, et al A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. J Cardiovasc Pharmacol 1988;12(Suppl 7):S64-6
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990;48:76-86
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386-92
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
   PubMed Web of Science ®Google Scholar
• Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. JAMA 1993;270:713-24
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA), Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER): Guidance for Industry: Population Pharmacokinetics, February 1999. Available at: http://www.fda.gov/CDER/guidance/1852fnl.pdf
   Google Scholar